ArticlePituitary2026
Focus on renal morphology, chronic kidney disease, and urinary system malignancies in acromegaly: report on data collected over a 40-year period.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-term renal consequences of acromegaly remain poorly characterized. We assessed prevalence and independent predictors of renal cysts, chronic kidney disease (CKD), and the frequency of urinary-system malignancies, in a large acromegaly cohort.
methods394 acromegaly patients managed at a single tertiary center over four decades were retrospectively evaluated. Renal cyst and CKD predictors were identified by binary multivariate logistic regression with sensitivity analyses including IGF-1 exposure metrics; eGFR trajectories by nested analysis of covariance (ANCOVA). Standardized prevalence (SPRs) and incidence (SIRs) ratios were computed against age- and sex-stratified population references.
resultsIn 394 patients (202 male; median disease duration 17 years), renal cysts were present in 41.0% of imaged patients (47.4% bilateral), CKD in 16.1%, and nephrolithiasis in 15.1%. Among CKD patients, 64.9% had preserved eGFR (KDIGO G1-G2), reflecting albuminuria- or structure-driven ascertainment. Independent cyst predictors were age, nephrolithiasis, liver cysts, and multiple neoplasms; higher baseline potassium was inversely associated (OR 0.37, p = 0.013). Independent CKD predictors were age, male sex, hypertension, and nephrolithiasis. Cross-sectional and cumulative GH/IGF-1×ULN did not predict either outcome; cumulative IGF-1 was positively associated with follow-up eGFR (β=+1.69, p = 0.022), consistent with hyperfiltration. Age-matched SPRs were 1.23-1.98 for cysts (both p < 0.05) and 0.67 for CKD (p = 0.002); urinary-system cancers showed a > 7-fold excess (SIR 7.38, 2.97-15.20; p < 0.001).
conclusionsRenal cysts, CKD, and urinary-system malignancies are prevalent in acromegaly, with the long-term renal burden predominantly morphological and tubular rather than glomerular. Cross-sectional and cumulative GH/IGF-1 metrics did not predict CKD; age-matched CKD prevalence was lower than expected while cyst prevalence was elevated. The cyst and urinary-cancer excess support dedicated renal surveillance in long-term acromegaly management.
Indexed as
Identifiers
42321588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.